Compare ZS & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZS | UTHR |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2B | 23.1B |
| IPO Year | 2018 | 1999 |
| Metric | ZS | UTHR |
|---|---|---|
| Price | $176.06 | $513.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 38 | 14 |
| Target Price | $264.94 | ★ $567.57 |
| AVG Volume (30 Days) | ★ 2.2M | 445.1K |
| Earning Date | 05-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.77 | 13.07 |
| EPS | N/A | ★ 13.07 |
| Revenue | N/A | ★ $1,483,300,000.00 |
| Revenue This Year | $27.83 | $6.39 |
| Revenue Next Year | $19.67 | $14.18 |
| P/E Ratio | ★ N/A | $39.26 |
| Revenue Growth | N/A | ★ 2.38 |
| 52 Week Low | $114.63 | $302.19 |
| 52 Week High | $336.99 | $609.35 |
| Indicator | ZS | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 57.71 | 44.14 |
| Support Level | $139.28 | $464.92 |
| Resistance Level | $179.90 | $516.36 |
| Average True Range (ATR) | 7.74 | 15.53 |
| MACD | -0.34 | 0.68 |
| Stochastic Oscillator | 58.68 | 43.90 |
Zscaler is a software-as-a-service, or SaaS, firm focusing on providing cloud-native cybersecurity solutions to primarily enterprise customers. Zscaler's offerings can be broadly partitioned into Zscaler Internet Access, which provides secure access to external applications, and Zscaler Private Access, which provides secure access to internal applications. The firm is headquartered in San Jose, California, and went public in 2018.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.